Search

Your search keyword '"Mourey, Loïc"' showing total 178 results
Start Over Author "Mourey, Loïc"
Sorry, I don't understand your search. ×
178 results on '"Mourey, Loïc"'

1. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database

Author

Cabart, Mathilde, Mourey, Loïc, Pasquier, David, Schneider, Sophie, Léna, Hervé, Girard, Nicolas, Chouaid, Christos, Schott, Roland, Hiret, Sandrine, Debieuvre, Didier, Quantin, Xavier, Madroszyk, Anne, Dubray-Longeras, Pascale, Pichon, Eric, Baranzelli, Anne, Justeau, Grégoire, Pérol, Maurice, Bosquet, Lise, and Cabarrou, Bastien

Published
2024
Full Text
View/download PDF

2. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

Author

Naffrichoux, Jérémie, Poupin, Pierre, Pouillot, William, Linassier, Claude, Rioux-Leclercq, Nathalie, De Vries-Brilland, Manon, Mourey, Loïc, Laguerre, Brigitte, Oudard, Stéphane, Gross-Goupil, Marine, Mousset, Coralie, Gravis, Gwenaelle, Rolland, Frédéric, Moise, Laura, Emambux, Sheik, Vassal, Cécile, Zanetta, Sylvie, Penel, Nicolas, Albiges, Laurence, Fromont, Gaëlle, and Cancel, Mathilde

Published
2024
Full Text
View/download PDF

3. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

Author

Yu, Evan Y., Berry, William R., Gurney, Howard, Retz, Margitta, Conter, Henry J., Laguerre, Brigitte, Fong, Peter C.C., Ferrario, Cristiano, Todenhöfer, Tilman, Gravis, Gwenaelle, Piulats, Josep M., Emmenegger, Urban, Shore, Neal D., Romano, Emanuela, Mourey, Loic, Li, Xin Tong, Poehlein, Christian H., Schloss, Charles, Appleman, Leonard J., and de Bono, Johann S.

Published
2024
Full Text
View/download PDF

5. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study

Author

Mourey, Loïc, Rainho, Larissa Tames, Dalban, Cécile, Carril-Ajuria, Lucía, Negrier, Sylvie, Chevreau, Christine, Gravis, Gwenaëlle, Thibault, Constance, Laguerre, Brigitte, Barthelemy, Philippe, Borchiellini, Delphine, Gross-Goupil, Marine, Geoffrois, Lionnel, Rolland, Frederic, Thiery-Vuillemin, Antoine, Tantot, Florence, Chaput, Nathalie, Naigeon, Marie, Teixeira, Marcus, Escudier, Bernard, Flippot, Ronan, and Albiges, Laurence

Published
2024
Full Text
View/download PDF

7. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Author

Yu, Evan Y., Kolinsky, Michael P., Berry, William R., Retz, Margitta, Mourey, Loic, Piulats, Josep M., Appleman, Leonard J., Romano, Emanuela, Gravis, Gwenaelle, Gurney, Howard, Bögemann, Martin, Emmenegger, Urban, Joshua, Anthony M., Linch, Mark, Sridhar, Srikala, Conter, Henry J., Laguerre, Brigitte, Massard, Christophe, Li, Xin Tong, Schloss, Charles, Poehlein, Christian H., and de Bono, Johann S.

Published
2022
Full Text
View/download PDF

9. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Author

Fizazi, Karim, Foulon, Stéphanie, Carles, Joan, Roubaud, Guilhem, McDermott, Ray, Fléchon, Aude, Tombal, Bertrand, Supiot, Stéphane, Berthold, Dominik, Ronchin, Philippe, Kacso, Gabriel, Gravis, Gwenaëlle, Calabro, Fabio, Berdah, Jean-François, Hasbini, Ali, Silva, Marlon, Thiery-Vuillemin, Antoine, Latorzeff, Igor, Mourey, Loïc, Laguerre, Brigitte, Abadie-Lacourtoisie, Sophie, Martin, Etienne, El Kouri, Claude, Escande, Anne, Rosello, Alvar, Magne, Nicolas, Schlurmann, Friederike, Priou, Frank, Chand-Fouche, Marie-Eve, Freixa, Salvador Villà, Jamaluddin, Muhammad, Rieger, Isabelle, and Bossi, Alberto

Published
2022
Full Text
View/download PDF

11. Tumors: Urologic Cancer

Author

Mourey, Loic, Hofman, Paul, Section editor, Boulahssass, Rabia, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

13. Digestive Organ Aging and Cancer

Author

Gerard, Stéphane, Steinmeyer, Zara, Lozano, Stéphanie, Garric, Marie, Girard, Philippe, Mourey, Loic, Deslandres, Marion, Abellan Van Kan, Gabor, Balardy, Laurent, Dale, William, Section editor, and Extermann, Martine, editor

Published
2020
Full Text
View/download PDF

15. Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial

Author

Orlando, Valentina, Drubay, Damien, Lavaud, Pernelle, Faivre, Laura, Lesaunier, François, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frédéric, Priou, Frank, Ferrero, Jean-Marc, Houede, Nadine, Mourey, Loic, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Grosse-Goupil, Marine, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Chinet-Charrot, Paule, Legouffe, Eric, Lagrange, Jean-Léon, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Davin, Jean-Louis, Martin, Anne-Laure, Brihoum, Meryem, Culine, Stéphane, Teuff, Gwénaël Le, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

21. Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer

Author

Jeannin, Gaelle, Patrick, Merle, Nehme, Hélène, Leroy, Virginie, De Mones Del Pujol, Erwan, Ravaud, Alain, Maget, Brigitte, Jovenin, Nicolas, Feugier, Pierre, Bologna, Serge, Comte, Brigitte, Falandry, Claire, Mailliez, Audrey, Villers, Arnauld, Rose, Christian, Bonnal, Jean-Louis, Minard, Aurélien, Gisselbrecht, Mathilde, Ladoire, Sylvain, Quipourt, Valérie, Lavau-Denes, Sandrine, Le Brun-Ly, Valérie, Thiberville, Luc, Rigal, Olivier, Lagrange, Jean Léon, Caillet, Philippe, Rousseau, Frédérique, De Decker, Laure, Bourbouloux, Emmanuelle, Carola, Elisabeth, Woerth, Florence, Brain, Etienne, Ribiere, Ludmilla, Stefani, Laeticia, Debray, Matthieu, Thieblemont, Catherine, Gisselbrecht, Christian, Balardy, Laurent, Mourey, Loic, Chaibi, Pascal, Frasca, M., Soubeyran, P., Bellera, C., Rainfray, M., Leffondre, K., and Mathoulin-Pélissier, S.

Published
2018
Full Text
View/download PDF

23. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial

Author

Blanchard, Pierre, Faivre, Laura, Lesaunier, François, Salem, Naji, Mesgouez-Nebout, Nathalie, Deniau-Alexandre, Elisabeth, Rolland, Frédéric, Ferrero, Jean-Marc, Houédé, Nadine, Mourey, Loïc, Théodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Davin, Jean-Louis, Habibian, Muriel, Culine, Stéphane, Laplanche, Agnès, and Fizazi, Karim

Published
2016
Full Text
View/download PDF

25. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Author

Fizazi, Karim, Faivre, Laura, Lesaunier, François, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frédéric, Priou, Frank, Ferrero, Jean-Marc, Houede, Nadine, Mourey, Loïc, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Ravaud, Alain, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Chinet-Charrot, Paule, Legouffe, Eric, Lagrange, Jean-Léon, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Davin, Jean-Louis, Martin, Anne-Laure, Habibian, Muriel, Laplanche, Agnès, and Culine, Stéphane

Published
2015
Full Text
View/download PDF

28. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Author

Gravis, Gwenaelle, Fizazi, Karim, Joly, Florence, Oudard, Stéphane, Priou, Franck, Esterni, Benjamin, Latorzeff, Igor, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Rolland, Fréderic, Théodore, Christine, Deplanque, Gael, Ferrero, Jean Marc, Pouessel, Damien, Mourey, Loïc, Beuzeboc, Philippe, Zanetta, Sylvie, Habibian, Muriel, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Labourey, Jean Luc, Machiels, Jean Pascal, El Kouri, Claude, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, and Soulie, Michel

Published
2013
Full Text
View/download PDF

29. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Author

UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Fizazi, Karim, Foulon, Stéphanie, Carles, Joan, Roubaud, Guilhem, McDermott, Ray, Fléchon, Aude, Tombal, Bertrand, Supiot, Stéphane, Berthold, Dominik, Ronchin, Philippe, Kacso, Gabriel, Gravis, Gwenaëlle, Calabro, Fabio, Berdah, Jean-François, Hasbini, Ali, Silva, Marlon, Thiery-Vuillemin, Antoine, Latorzeff, Igor, Mourey, Loïc, Laguerre, Brigitte, Abadie-Lacourtoisie, Sophie, Martin, Etienne, El Kouri, Claude, Escande, Anne, Rosello, Alvar, Magne, Nicolas, Schlurmann, Friederike, Priou, Frank, Chand-Fouche, Marie-Eve, Freixa, Salvador Villà, Jamaluddin, Muhammad, Rieger, Isabelle, Bossi, Alberto, PEACE-1 investigators, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Fizazi, Karim, Foulon, Stéphanie, Carles, Joan, Roubaud, Guilhem, McDermott, Ray, Fléchon, Aude, Tombal, Bertrand, Supiot, Stéphane, Berthold, Dominik, Ronchin, Philippe, Kacso, Gabriel, Gravis, Gwenaëlle, Calabro, Fabio, Berdah, Jean-François, Hasbini, Ali, Silva, Marlon, Thiery-Vuillemin, Antoine, Latorzeff, Igor, Mourey, Loïc, Laguerre, Brigitte, Abadie-Lacourtoisie, Sophie, Martin, Etienne, El Kouri, Claude, Escande, Anne, Rosello, Alvar, Magne, Nicolas, Schlurmann, Friederike, Priou, Frank, Chand-Fouche, Marie-Eve, Freixa, Salvador Villà, Jamaluddin, Muhammad, Rieger, Isabelle, Bossi, Alberto, and PEACE-1 investigators

Abstract

Current standard of care for metastatic castration-sensitive prostate cancer supplements androgen deprivation therapy with either docetaxel, second-generation hormonal therapy, or radiotherapy. We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care. We conducted an open-label, randomised, phase 3 study with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland. Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 due to bone pain). Participants were randomly assigned (1:1:1:1) to standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m once every 3 weeks), standard of care plus radiotherapy, standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily), or standard of care plus radiotherapy plus abiraterone. Neither the investigators nor the patients were masked to treatment allocation. The coprimary endpoints were radiographic progression-free survival and overall survival. Abiraterone efficacy was first assessed in the overall population and then in the population who received androgen deprivation therapy with docetaxel as standard of care (population of interest). This study is ongoing and is registered with ClinicalTrials.gov, NCT01957436. Between Nov 27, 2013, and Dec 20, 2018, 1173 patients were enrolled (one patient subsequently withdrew consent for analysis of his data) and assigned to receive standard of care (n=296), standard of care plus radiotherapy (n=293), standard of care plus abiraterone (n=292), or standard of care plus radiotherapy plus abiraterone (n=291). Median follow-up was 3·5 years (IQR 2·8-4·6) for radiographic progression-free survival an

Published
2022

30. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Author

Fizazi, Karim, Lesaunier, Francois, Delva, Remy, Gravis, Gwenaëlle, Rolland, Frederic, Priou, Frank, Ferrero, Jean-Marc, Houedé, Nadine, Mourey, Loïc, Theodore, Christine, Krakowski, Ivan, Berdah, Jean-François, Baciuchka, Marjorie, Laguerre, Brigitte, Fléchon, Aude, Ravaud, Alain, Cojean-Zelek, Isabelle, Oudard, Stéphane, Labourey, Jean-Luc, Lagrange, Jean-Léon, Chinet-Charrot, Paule, Linassier, Claude, Deplanque, Gaël, Beuzeboc, Philippe, Geneve, Jean, Davin, Jean-Louis, Tournay, Elodie, and Culine, Stephane

Published
2012
Full Text
View/download PDF

32. Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial

Author

Brain, Etienne G.C., Mertens, Cécile, Girre, Véronique, Rousseau, Frédérique, Blot, Emmanuel, Abadie, Sophie, Uwer, Lionel, Bourbouloux, Emmanuelle, Van Praagh-Doreau, Isabelle, Mourey, Loic, Kirscher, Sylvie, Laguerre, Brigitte, Fourme, Emmanuelle, Luneau, Sylvia, Genève, Jean, and Debled, Marc

Published
2011
Full Text
View/download PDF

33. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

Author

Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T. K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P. J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T., Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, and Wolter, Pascal

Published
2015
Full Text
View/download PDF

34. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Author

Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie-Ange, TINQUAUT, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude-Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D’Hondt, Veronique, Lortholary, Alain, Brachet, Pierre-Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, Freyer, Gilles, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), and UNICANCER

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021

35. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study

Author

Joly, Florence, Delva, Remy, Mourey, Loïc, Sevin, Emmanuel, Bompas, Emmanuelle, Vedrine, Lionel, Ravaud, Alain, Eymard, Jean-Christophe, Tubiana-Mathieu, Nicole, Linassier, Claude, Houede, Nadine, Guillot, Aline, Ringensen, François, Cojocarasu, Oana, Valenza, Bruno, Leconte, Alexandra, Lheureux, Stéphanie, Clarisse, Bénédicte, and Oudard, Stéphane

Published
2015
Full Text
View/download PDF

36. Spreading geriatric oncology culture through professional caregivers: Results of a French massive open online course (MOOC)

Author

Nicolas, Charlotte, primary, Balardy, Laurent, additional, Antoine, Valery, additional, Albarède, Julie, additional, Azria, David, additional, Cristol, Laurence, additional, Ferreira, Ernestine, additional, Gérard, Stéphane, additional, Jeandel, Claude, additional, Louit, Camille, additional, Tranier, Alexandrine, additional, Ufkes, Rosanne, additional, Bauvin, Eric, additional, Morel, Charlotte, additional, and Mourey, Loïc, additional

Published
2021
Full Text
View/download PDF

37. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin plus Paclitaxel for Vulnerable Older Adult Women with Ovarian Cancer:A GINECO/GCIG Randomized Clinical Trial

Author

Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie Ange, Tinquaut, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D'Hondt, Veronique, Lortholary, Alain, Brachet, Pierre Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, Freyer, Gilles, Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie Ange, Tinquaut, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D'Hondt, Veronique, Lortholary, Alain, Brachet, Pierre Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, and Freyer, Gilles

Abstract

Importance: Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients. Objective: To compare the feasibility, efficacy, and safety of single-agent carboplatin every 3 weeks, weekly carboplatin-paclitaxel, or conventional every-3-weeks carboplatin-paclitaxel in vulnerable older patients with ovarian cancer. Design, Setting, and Participants: This international, open-label, 3-arm randomized clinical trial screened 447 women 70 years and older with newly diagnosed stage III/IV ovarian cancer by determining their Geriatric Vulnerability Score; 120 patients with a Geriatric Vulnerability Score of 3 or higher were stratified by country and surgical outcome. Enrollment took place at 48 academic centers in France, Italy, Finland, Denmark, Sweden, and Canada from December 11, 2013, to April 26, 2017. Final analysis database lock April 2019. Data analysis was performed from February 1 to December 31, 2019. Interventions: Patients were randomized to receive 6 cycles of (1) carboplatin, area under the curve (AUC) 5 mg/mL·min, plus paclitaxel, 175 mg/m2, every 3 weeks; (2) single-agent carboplatin, AUC 5 mg/mL·min or AUC 6 mg/mL·min, every 3 weeks; or (3) weekly carboplatin, AUC 2 mg/mL·min, plus paclitaxel, 60 mg/m2, on days 1, 8, and 15 every 4 weeks. Main Outcomes and Measures: The primary outcome was treatment feasibility, defined as the ability to complete 6 chemotherapy cycles without disease progression, premature toxic effects-related treatment discontinuation, or death. Results: A total of 120 women were randomized. The mean and median age was 80 (interquartile range, 76-83; range, 70-94) years; 43 (36%) had a Geriatric Vulnerability Score of 4 and 13 (11%) had a Geriatric Vulnerability Score of 5; 40 (33%) had stage IV disease. During its third meeting, the independent data m

Published
2021

39. Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Author

Chevreau, Christine, primary, Massard, Christophe, additional, Flechon, Aude, additional, Delva, Rémy, additional, Gravis, Gwenaëlle, additional, Lotz, Jean‐Pierre, additional, Bay, Jacques‐Olivier, additional, Gross‐Goupil, Marine, additional, Fizazi, Karim, additional, Mourey, Loïc, additional, Paci, Angelo, additional, Guitton, Jérôme, additional, Thomas, Fabienne, additional, Lelièvre, Bénédicte, additional, Ciccolini, Joseph, additional, Moeung, Sotheara, additional, Gallois, Yohan, additional, Olivier, Pascale, additional, Culine, Stéphane, additional, Filleron, Thomas, additional, and Chatelut, Etienne, additional

Published
2021
Full Text
View/download PDF

40. Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies

Author

Garric, Marie, primary, Sourdet, Sandrine, additional, Cabarrou, Bastien, additional, Steinmeyer, Zara, additional, Gauthier, Martin, additional, Ysebaert, Loïc, additional, Beyne‐Rauzy, Odile, additional, Gerard, Stephane, additional, Lozano, Stephanie, additional, Brechemier, Delphine, additional, Filleron, Thomas, additional, Mourey, Loïc, additional, and Balardy, Laurent, additional

Published
2021
Full Text
View/download PDF

42. Perspectives on cancer care in older patients in France

Author

Hauchecorne, Mathilde, primary, Pierro, Monica, additional, Brain, Etienne, additional, Bringuier, Michael, additional, Soubeyran, Pierre, additional, Chakiba, Camille, additional, Mathoulin-Pelissier, Simone, additional, Paillaud, Elena, additional, Geiss, Romain, additional, Besse, Benjamin, additional, Mourey, Loïc, additional, Vincent, Hélène, additional, and Baldini, Capucine, additional

Published
2020
Full Text
View/download PDF

43. Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy

Author

Ploussard, Guillaume, primary, Pradere, Benjamin, additional, Beauval, Jean-Baptiste, additional, Chevreau, Christine, additional, Almeras, Christophe, additional, Suc, Etienne, additional, Gautier, Jean-Romain, additional, Laurenty, Anne-Pascale, additional, Roumiguié, Mathieu, additional, Loison, Guillaume, additional, Tollon, Christophe, additional, Mourey, Loïc, additional, Salin, Ambroise, additional, Xylinas, Evanguelos, additional, and Pouessel, Damien, additional

Published
2020
Full Text
View/download PDF

46. Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40]

Author

Auvray, Marie, primary, Auclin, Edouard, additional, Barthelemy, Philippe, additional, Bono, Petri, additional, Kellokumpu-Lehtinen, Pirkko, additional, Gross-Goupil, Marine, additional, De Velasco, Guillermo, additional, Powles, Thomas, additional, Mouillet, Guillaume, additional, Vano, Yann-Alexandre, additional, Gravis, Gwenaëlle, additional, Mourey, Loïc, additional, Priou, Franck, additional, Rolland, Frédéric, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2019
Full Text
View/download PDF

47. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Author

Auvray, Marie, primary, Auclin, Edouard, additional, Barthelemy, Philippe, additional, Bono, Petri, additional, Kellokumpu-Lehtinen, Pirkko, additional, Gross-Goupil, Marine, additional, De Velasco, Guillermo, additional, Powles, Thomas, additional, Mouillet, Guillaume, additional, Vano, Yann-Alexandre, additional, Gravis, Gwenaëlle, additional, Mourey, Loïc, additional, Priou, Franck, additional, Rolland, Frédéric, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2019
Full Text
View/download PDF

48. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean-Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, Fizazi, Karim, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Lavaud, Pernelle, Gravis, Gwenaëlle, Foulon, Stéphanie, Joly, Florence, Oudard, Stéphane, Priou, Frank, Latorzeff, Igor, Mourey, Loïc, Soulié, Michel, Delva, Remy, Krakowski, Ivan, Laguerre, Brigitte, Théodore, Christine, Ferrero, Jean Marc, Beuzeboc, Philippe, Habibian, Muriel, Rolland, Frédéric, Deplanque, Gael, Pouessel, Damien, Zanetta, Sylvie, Berdah, Jean François, Dauba, Jerome, Baciuchka, Marjorie, Platini, Christian, Linassier, Claude, Tubiana-Mathieu, Nicole, Machiels, Jean-Pascal, Kouri, Claude El, Ravaud, Alain, Suc, Etienne, Eymard, Jean Christophe, Hasbini, Ali, Bousquet, Guilhem, Culine, Stéphane, Boher, Jean-Marie, Tergemina-Clain, Gabrielle, Legoupil, Clémence, and Fizazi, Karim

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for mCNPC. OBJECTIVE: To investigate the efficacy and tolerance of subsequent treatments in patients treated upfront with chemo-hormonal therapy for mCNPC. DESIGN, SETTING, AND PARTICIPANTS: Retrospective data from the GETUG-AFU 15 phase 3 trial were collected for treatments received for mCRPC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For the first three lines of salvage treatment for mCRPC we investigated the biochemical progression-free survival, maximum prostate-specific antigen (PSA) decline, overall survival, and tolerance. RESULTS AND LIMITATIONS: Overall, 245 patients received at least one treatment for mCRPC. For docetaxel used in first-line, a PSA decline ≥50% was observed in 25/66 (38%) and in 4/20 patients (20%) who had received upfront ADT alone and ADT plus docetaxel (p=0.14). The median biochemical progression-free survival was 6.0 mo (95% confidence interval: 3.6-7.7) and 4.1 mo (95% confidence interval: 1.3-4.9), respectively. For docetaxel used in first- or second-line, a PSA decline ≥50% was observed in 36/80 (45%) and in 4/29 patients (14%) who had received upfront ADT alone and ADT plus docetaxel (p=0.07). PSA declines ≥50% were observed with bicalutamide in 12/28 (43%) and 4/23 patients (17%) who had received upfront ADT alone and ADT plus docetaxel. Among men treated upfront with ADT plus docetaxel who received abiraterone or enzalutamide for mCRPC, 10/19 patients (53%) achieved a PSA decline ≥50%. Few grade 3-4 events occurred. Study limitations include the observational design and retrospective characteristics of this analysis, without standardized therapeutic salv

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results